Astroglial c-Myc Overexpression Predisposes Mice to Primary Malignant Gliomas*

Malignant astrocytomas are common human primary brain tumors that result from neoplastic transformation of astroglia or their progenitors. Here we show that deregulation of the c-Myc pathway in developing astroglia predisposes mice to malignant astrocytomas within 2–3 weeks of age. The genetically engineered murine (GEM) gliomas harbor a molecular signature resembling that of human primary glioblastoma multiforme, including up-regulation of epidermal growth factor receptor and Mdm2. The GEM gliomas seem to originate in an abnormal population of glial fibrillary acidic protein-expressing cells in the ventricular zone and, analogous to human glioblastomas, exhibit molecular and morphological heterogeneity. Levels of connexin 43 in the majority of the tumors are unaltered from normal tissue, indicating that GEM tumors have retained the capacity to establish syncytial networks. In line with this, individual glioma foci are composed of a mixture of actively proliferating cells expressing c-Myc and proliferating cell nuclear antigen and less dividing bystander cells that express glial fibrillary acidic protein and the broad complex tramtrack bric-a-brac/poxvirus and zinc finger domain protein HOF. A subset of the transgenic mice harbored, in addition to brain tumors, vestigial cerebellums in which granule cell migration and radial Bergman glial cell differentiation were disturbed. These observations argue for a window of vulnerability during astrocyte development where c-Myc overexpression is sufficient to trigger the neoplastic process, presumably by inducing the sustained growth of early astroglial cells. This is in contrast to most other transgenic studies in which c-Myc overexpression requires co-operating transgenes for rapid tumor induction.

[1]  M. Barone,et al.  Myc but not Fos rescue of PDGF signalling block caused by kinase-inactive Src , 1995, Nature.

[2]  M. Papadopoulos,et al.  Aquaporin-4 expression is increased in oedematous human brain tumours , 2002, Journal of neurology, neurosurgery, and psychiatry.

[3]  M. Nedergaard,et al.  Direct gap junction communication between malignant glioma cells and astrocytes. , 1999, Cancer research.

[4]  E. Zimmerman,et al.  Fibrillary astrocytes proliferate in response to brain injury: a study combining immunoperoxidase technique for glial fibrillary acidic protein and radioautography of tritiated thymidine. , 1979, Developmental biology.

[5]  D. Wechsler,et al.  MXI1, a putative tumor suppressor gene, suppresses growth of human glioblastoma cells. , 1997, Cancer research.

[6]  R. Warnick,et al.  Protein and messenger RNA expression of connexin43 in astrocytomas: implications in brain tumor gene therapy. , 1996, Journal of neurosurgery.

[7]  Dan Goldowitz,et al.  The cells and molecules that make a cerebellum , 1998, Trends in Neurosciences.

[8]  Ruo-Pan Huang,et al.  Reduced connexin43 expression in high‐grade human brain glioma cells , 1999, Journal of surgical oncology.

[9]  J. Garvey,et al.  Transgenic mouse model for neurocristopathy: Schwannomas and facial bone tumors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Georg Breier,et al.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.

[11]  H. Engelhard,et al.  Quantification of the c-myc oncoprotein in human glioblastoma cells and tumor tissue. , 1989, Journal of neurosurgery.

[12]  M. Hatten,et al.  Mechanisms of neural patterning and specification in the developing cerebellum. , 1995, Annual review of neuroscience.

[13]  D. Louis,et al.  Focus on central nervous system neoplasia. , 2002, Cancer cell.

[14]  F. Kirchhoff,et al.  GFAP promoter‐controlled EGFP‐expressing transgenic mice: A tool to visualize astrocytes and astrogliosis in living brain tissue , 2001, Glia.

[15]  J. Sedivy,et al.  Transactivation-defective c-MycS retains the ability to regulate proliferation and apoptosis. , 1998, Genes & development.

[16]  K. Ichimura,et al.  Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades , 1998, Genes, chromosomes & cancer.

[17]  R. Eisenman,et al.  The Myc/Max/Mad network and the transcriptional control of cell behavior. , 2000, Annual review of cell and developmental biology.

[18]  B. Gusterson,et al.  Inducible ablation of astrocytes shows that these cells are required for neuronal survival in the adult brain , 2001, Glia.

[19]  M. Gishizky,et al.  SU6656, a Selective Src Family Kinase Inhibitor, Used To Probe Growth Factor Signaling , 2000, Molecular and Cellular Biology.

[20]  S. Mai,et al.  The ribonucleotide reductase R2 gene is a non-transcribed target of c-Myc-induced genomic instability. , 1999, Gene.

[21]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[22]  Webster K. Cavenee,et al.  The WHO Classification of Tumors of the Nervous System , 2002 .

[23]  D. Lane,et al.  Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. , 1990, Journal of cell science.

[24]  S. Mai,et al.  Myc-induced cyclin D2 genomic instability in murine B cell neoplasms. , 1999, Current topics in microbiology and immunology.

[25]  M. Oren,et al.  Mdm2: The Ups and Downs , 1999, Molecular medicine.

[26]  M. Cole,et al.  The Novel ATM-Related Protein TRRAP Is an Essential Cofactor for the c-Myc and E2F Oncoproteins , 1998, Cell.

[27]  R. DePinho,et al.  Malignant glioma: genetics and biology of a grave matter. , 2001, Genes & development.

[28]  S. Mai,et al.  c-Myc overexpression associated DHFR gene amplification in hamster, rat, mouse and human cell lines. , 1996, Oncogene.

[29]  Rosalie C Sears,et al.  Signaling Networks That Link Cell Proliferation and Cell Fate* , 2002, The Journal of Biological Chemistry.

[30]  B. Lüscher,et al.  Function and regulation of the transcription factors of the Myc/Max/Mad network. , 2001, Gene.

[31]  M. West,et al.  Failure of central nervous system myelination in MBP/c-myc transgenic mice: evidence for c-myc cytotoxicity , 1998, Oncogene.

[32]  D. Spray,et al.  From neuro‐glue (‘nervenkitt’) to glia: A prologue , 1998, Glia.

[33]  Christian Giaume,et al.  Pathways of neuron-astrocyte interactions and their possible role in neuroprotection , 2001, European Archives of Psychiatry and Clinical Neuroscience.

[34]  M. Luskin,et al.  Divergent lineages for oligodendrocytes and astrocytes originating in the neonatal forebrain subventricular zone , 1994, Glia.

[35]  M. Papadopoulos,et al.  Emerging molecular mechanisms of brain tumour oedema. , 2001, British journal of neurosurgery.

[36]  Hans-Christian Pedersen,et al.  Characterization of Two Novel Nuclear BTB/POZ Domain Zinc Finger Isoforms , 2002, Journal of Biological Chemistry.

[37]  G. D. Spotts,et al.  Identification of downstream-initiated c-Myc proteins which are dominant-negative inhibitors of transactivation by full-length c-Myc proteins , 1997, Molecular and cellular biology.

[38]  D. Felsher,et al.  Transient excess of MYC activity can elicit genomic instability and tumorigenesis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Maria Julia Marinissen,et al.  Regulation of c-myc expression by PDGF through Rho GTPases , 2001, Nature Cell Biology.

[40]  L. Soroceanu,et al.  Reduced expression of connexin‐43 and functional gap junction coupling in human gliomas , 2001, Glia.

[41]  K. Ryan,et al.  Myc oncogenes: the enigmatic family. , 1996, The Biochemical journal.

[42]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[43]  A. Feinberg,et al.  Evidence for rearrangement, amplification, and expression of c-myc in a human glioblastoma. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[44]  M. West,et al.  Oligodendrocyte Programmed Cell Death and Central Myelination Deficiency Induced in Transgenic Mice by Synergism between c-Myc and Oct-6* , 1999, The Journal of Biological Chemistry.

[45]  M Koslow,et al.  Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. , 1994, Journal of neurosurgery.

[46]  Y Taya,et al.  Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. , 2000, Genes & development.

[47]  A. Messing,et al.  GFAP promoter directs astrocyte-specific expression in transgenic mice , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.